Promises of PAR-1 inhibition in acute coronary syndrome

Current Cardiology Reports

Volumn 14, Issue 1, 2012, Pages 32-39

  Leonardi, Sergio ^a,b   Tricoci, Pierluigi ^a   Mahaffey, Kenneth W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Acute coronary syndromes; Atopaxar; PAR 1 inhibitors; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ATOPAXAR; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; HEPARIN; KETOCONAZOLE; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; RIFAMPICIN; THROMBIN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; TICAGRELOR; TICLOPIDINE; VORAPAXAR;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CORONARY ARTERY BYPASS GRAFT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HEART DEATH; HEART INFARCTION; HUMAN; LIVER DYSFUNCTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ASPIRIN; FEMALE; HUMANS; IMINES; LACTONES; MALE; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, PAR-1; RECURRENCE; TREATMENT OUTCOME;

EID: 84857638522     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0232-z     Document Type: Article

References (34)

1. M Naghavi P Libby E Falk, et al. 2003 From Vulnerable Plaque to Vulnerable Patient Circulation 108 1664 1672 14530185 10.1161/01.CIR.0000087480. 94275.97 (Pubitemid 37243650)
2. V Fuster JM Sweeny 2011 Aspirin Circulation 123 768 778 21343593 10.1161/CIRCULATIONAHA.110.963843 This is an excellent review on the most widely used antiplatelet agent, aspirin
3. JJBC Thebault JF Blanchard EA Panak 1975 Effects of ticlopidine, a new platelet aggregation inhibitor in man Clin Pharmacol Ther 18 485 490 1100310 1:CAS:528:DyaE28XktVI%3D
4. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 494 502 10.1056/NEJMoa010746 (Pubitemid 32758501)
5. SR Mehta S Yusuf RJG Peters, et al. 2001 Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 527 533 11520521 10.1016/S0140-6736(01)05701-4 1:CAS:528:DC%2BD3MXmtV2ht7g%3D (Pubitemid 32772726)
6. SR Steinhubl PB Berger JT Mann, et al. 2002 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention JAMA 288 2411 2420 12435254 10.1001/jama.288.19.2411 1:CAS:528:DC%2BD38XoslOksL0%3D (Pubitemid 35340537)
7. L Wallentin C Varenhorst S James, et al. 2008 Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 21 30 18055486 10.1093/eurheartj/ ehm545 1:CAS:528:DC%2BD1cXis1Sqtr8%3D
8. L Wallentin RC Becker A Budaj, et al. 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045 1057 19717846 10.1056/NEJMoa0904327 1:CAS:528:DC%2BD1MXhtFaltL%2FJ
9. DL Bhatt AM Lincoff CM Gibson, et al. 2009 Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2330 2341 19915222 10.1056/NEJMoa0908629 1:CAS:528:DC%2BD1MXhsFGltr7P
10. RA Harrington GW Stone S McNulty, et al. 2009 Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2318 2329 19915221 10.1056/NEJMoa0908628 1:CAS:528:DC%2BD1MXhsFGlsbfF
11. S Leonardi SV Rao RA Harrington, et al. 2010 Rationale and design of the randomized, double-blind trial testing INtraveNous and oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-PCI) Am Heart J 160 65 72 20598974 10.1016/j.ahj.2010.04.008 1:CAS:528:DC%2BC3cXosVWnsr8%3D
12. SD Wiviott E Braunwald CH McCabe, et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2001 2015 17982182 10.1056/NEJMoa0706482 1:CAS:528:DC%2BD2sXhtlWis7rN (Pubitemid 350106708)
13. JW Eikelboom JI Weitz A Budaj, et al. 2002 Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes Eur Heart J 23 1771 1779 12419297 10.1053/euhj.2000.3234 1:CAS:528:DC%2BD38XpsV2nsbo%3D (Pubitemid 35334270)
14. JR Hamilton I Cornelissen SR Coughlin 2004 Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets J Thromb Haemost 2 1429 1435 15304051 10.1111/j.1538-7836.2004.00783.x 1:CAS:528:DC%2BD2cXns1aisL0%3D (Pubitemid 40186142)
15. MVS Chintala S Kurowski C Sabin D Reynolds K Prevete G Friedrichs 2008 SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys Atheroscler Thromb Vasc Biol 28 e32 e149 10.1161/01.ATV.0000319737.80976.26 Abstract P579
16. PA Gurbel US Tantry 2010 Combination antithrombotic therapies Circulation 121 569 583 20124137 10.1161/CIRCULATIONAHA.109.853085 This is an important review on the rationale of combining antiplatelet agents and their applications
17. M Chintala J Strony B Yang S Kurowski Q Li 2010 SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a folts model of arterial thrombosis in cynomolgus monkeys Arterioscler Thromb Vasc Biol 30 2143 2149 20798382 10.1161/ATVBAHA.110.203414 1:CAS:528:DC%2BC3cXhtlSqtb%2FJ
18. G Davì C Patrono 2007 Platelet activation and atherothrombosis N Engl J Med 357 2482 2494 18077812 10.1056/NEJMra071014 (Pubitemid 350272787)
19. SR Coughlin 2000 Thrombin signalling and protease-activated receptors Nature 407 258 264 11001069 10.1038/35025229 1:CAS:528:DC%2BD3cXmvVSls7w%3D
20. ML Kahn M Nakanishi-Matsui MJ Shapiro H Ishihara SR Coughlin 1999 Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin J Clin Invest 103 879 887 10079109 10.1172/JCI6042 1:CAS:528: DyaK1MXhvFarsro%3D (Pubitemid 29152634)
21. RC Becker DJ Moliterno LK Jennings, et al. 2009 Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 919 928 19286091 10.1016/S0140-6736(09)60230-0 1:CAS:528: DC%2BD1MXjtFKqtrs%3D
22. A Ghosal X Lu N Penner, et al. 2011 Identification of human liver cytochrome p450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist Drug Metab Dispos 39 30 38 20926621 10.1124/dmd.110.035493 1:CAS:528:DC%2BC3MXls1emsA%3D%3D
23. Doc ID 3303095. SCH 530348: influence of chronic renal disease and hemodialysis on the single-dose pharmacokinetics and pharmacodynamics of SCH 530348 [study report for protocol P03464]. Kenilworth (NJ): Schering-Plough Research Institute. 2005.
24. SYT Goto Y Ikeda K Kato H Yamaguchi P Jensen 2010 Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome J Atheroscler Thromb 17 156 164 20124733 10.5551/jat.3038 1:CAS:528:DC%2BC3MXhvVeru7w%3D
25. Shinohara Y, Goto S, Doi M, Jensen P. Safety of the Novel Protease-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with a History of Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases;In Press, Corrected Proof.
26. TRACER The 2009 Executive steering C. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA-CER) trial: study design and rationale Am Heart J 158 327 334 10.1016/j.ahj.2009.07.001
27. DA Morrow BM Scirica KAA Fox, et al. 2009 Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial Am Heart J 158 335 341.e3 19699854 10.1016/j.ahj.2009.06. 027 1:CAS:528:DC%2BD1MXhtVegs7bL
28. M Kogushi T Matsuoka T Kawata, et al. 2011 The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs Eur J Pharmacol 657 131 137 21300059 10.1016/j.ejphar.2011.01.058 1:CAS:528:DC%2BC3MXjtFGrtLk%3D
29. M Kogushi T Matsuoka H Kuramochi, et al. 2011 Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats Eur J Pharmacol 666 158 164 21635884 10.1016/j.ejphar.2011.05.034 1:CAS:528:DC%2BC3MXosVGltLw%3D
30. KM Serebruany VL D Dastros-Pitei M Flather DL Bhatt 2009 he in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thromb Haemost 102 111 119 19572075
31. A Tello-Montoliu SD Tomasello M Ueno DJ Angiolillo 2011 Antiplatelet therapy: thrombin receptor antagonists Br J Clin Pharmacol 72 658 671 21906120 10.1111/j.1365-2125.2010.03884.x 1:CAS:528:DC%2BC3MXhtlers7rK
32. S Goto H Ogawa M Takeuchi MD Flather DL Bhatt 2010 Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur Heart J 3 2601 2613 10.1093/eurheartj/ ehq320
33. ML O'Donoghue DL Bhatt SD Wiviott, et al. 2011 Safety and tolerability of atopaxar in the treatment of patients with acute cronary syndromes/clinical perspective Circulation 123 1843 1853 21502577 10.1161/CIRCULATIONAHA.110.000786
34. SD Wiviott MD Flather ML O'Donoghue, et al. 2011 Randomized trial of atopaxar in the treatment of patients with coronary artery disease/clinical perspective Circulation 123 1854 1863 21502571 10.1161/CIRCULATIONAHA.110.001404 1:CAS:528:DC%2BC3MXlsVynsbw%3D